Guangshengtang announced that the company plans to sign a “technology transfer contract” with the related party Ruitai to transfer all technology and rights in the divenlafaxine succinate sustained-release tablet project, with a transaction amount of 126.36 million yuan. The drug is used to treat severe depression in adults, helps to enrich the company's product pipeline and strengthen sales collaboration with existing products. Retailai's divenlafaxine succinate extended-release tablets have completed process verification for 50 mg and 25 mg specifications and bioequivalence studies for 50 mg specifications, and have obtained an invention patent for an oral solid preparation and its preparation method, and has not yet submitted a drug registration and marketing application. This transaction constitutes a related transaction and has been reviewed and approved by the board of directors.

Guangshengtang announced that the company plans to sign a “technology transfer contract” with the related party Ruitai to transfer all technology and rights in the divenlafaxine succinate sustained-release tablet project, with a transaction amount of 126.36 million yuan. The drug is used to treat severe depression in adults, helps to enrich the company's product pipeline and strengthen sales collaboration with existing products. Retailai's divenlafaxine succinate extended-release tablets have completed process verification for 50 mg and 25 mg specifications and bioequivalence studies for 50 mg specifications, and have obtained an invention patent for an oral solid preparation and its preparation method, and has not yet submitted a drug registration and marketing application. This transaction constitutes a related transaction and has been reviewed and approved by the board of directors.